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PREFACE 
In spite of the huge progress made in the treatment of tumors in the last thirty years, 
for some tumors, such as osteosarcoma, the survival rate of the patients treated with the 
combination of multi-agent chemotherapy and surgery has not improved. This could be 
explained in part because chemotherapy is not selective for tumor cells, but also kills normal 
cells that are in active cell division. Thus, if the toxicity of the multiagent chemotherapy is 
increased, normal tissue will also be damaged. In order to improve patient’s survival rate, 
innovative treatments that specifically target osteosarcoma cells should be developed.  
Mesenchymal stem cells are currently tested in more than 500 clinical trials to treat 
patients affected by conditions that range from traumatic and degenerative damages of tissues 
to the treatment of graft versus host diseases. Mesenchymal stem cells are also attracted by 
alteration of the tissue architecture caused by malignant cancer growth. This tumor-homing 
property makes mesenchymal stem cells an ideal cellular candidate to deliver selectively 
therapeutic agents to tumor cells.  
In this context, this PhD project concerns two proofs of concept. The first being that 
when mesenchymal stem cells are used as a cellular vehicle to deliver photoactivable 
nanoparticles, they can induce osteosarcoma cell death. Secondly, nanoparticles decorated 
with a photosensitizer that can be activated in the near infrared region of the visible spectrum, 
once photostimulated, can induce tumor growth inhibition in mice bearing tumors.  
An introduction, including the related references, provides the overview of the PhD 
project scenario. A second section reports the general aims of the thesis and the experimental 
part that is divided into two chapters concerning the investigated application fields. Published 
or submitted for publication results, supported by their specific references, are reported in the 
third section. Final conclusions and future perspectives complete the present thesis. 
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INTRODUCTION 
1. Osteosarcoma 
Sarcomas are malignant tumors that originate in bones, cartilage, fat, nerves and blood 
vessels. Among the sarcomas, high grade osteosarcoma (OS) is the most common primary 
bone tumor. OS generally develops in the long bones of adolescents. Standard treatment for 
OS includes multi-agent neoadjuvant chemotherapy, surgery and multi-agent adjuvant 
chemotherapy. Radiotherapy can also be used. The 5-year event free survival (EFS) of OS 
patients with nonmetastatic disease at presentation is 70% (Longhi, Errani, De Paolis, 
Mercuri, & Bacci, 2006). Between 20-25% of the OS patients develop metastasis. In over 
90% of the cases, the metastasis develops in the lungs and is the first cause of disease 
mortality. For patients with metastasis at presentation the EFS is below 40%. Patients with 
bilateral metastasis have worse outcomes than monolateral (Ferrari & Serra, 2015)(Bacci et 
al., 2008).  
In spite of the huge effort made in the last 30 years to improve patient’s survival rate, 
little progress has been made and the prognosis of OS has plateaued since 1990. The major 
limitation of the current therapeutic protocols is the lack of tumor targeting. This could be 
explained in part because chemotherapy is given systemically and lacks precise specificity to 
target only malignant cells, it is known that chemotherapy also kills healthy cells that are in 
active cell division. As a consequence, healthy tissues are also damaged when the toxicity of 
the drugs is increased. Thus, the development of novel alternative strategies to current 
standard treatment is needed. In particular it is important that the innovative therapeutic 
agents have an increased capacity to selectively eliminate cancer cells as well as reduce the 
toxicity in healthy tissues. Currently, alternative treatments to standard therapy are being 
tested in clinical trials for OS patients, particularly therapeutic approaches that have shown to 
be effective for several types of advanced tumors. For example immunotherapies, such as 
vaccination and cytokine therapy, have been investigated for OS treatment (Uehara et al., 
2015). However, these therapeutic agents are short lived, are toxic when administrated at high 
doses, and are constantly cleared by specialized cells and organs. Therefore, new therapeutic 
strategies that are able to deliver therapeutic agents directly to the tumor cells at elevated 
concentrations shielded from the immune system must be developed.  
In 2002 Dr. Studeny published findings that mesenchymal stem cells (MSCs) can be 
used as delivery vehicles to selectively transport therapeutic agents to cancer cells because 
they have selective tropism for tumors and also because MSCs are immunosuppressive and 
can evade the immune system (Studeny et al., 2002). This therapeutic approach, named the 
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Trojan horse strategy, is important because MSCs can be exploited to deliver anticancer 
agents to the tumor microenvironment. 
2. Mesenchymal stem cells 
MSCs were first identified in 1966 as osteogenic cells (Friedenstein, 1966). MSCs are 
fibroblast–like cells that reside in many adult, perinatal, and fetal tissues. For example, MSCs 
reside in bone marrow where they represent a small population, about 0.001-0.01% of the 
cells (Muschler, Nitto, Boehm, & Easley, 2001). In physiological conditions, MSCs have a 
key role in the support of the stem cell niche. MSCs live close to hematopoietic stem cells in 
the bone marrow and provide for their survival (Chitteti et al., 2010). MSCs also constitute a 
local reservoir of cells that in time of stress or injury, can be recruited by solid organs to 
promote tissue repair. MSCs are functionally plastic cells that can sense clues from the local 
microenvironment and respond accordingly. After injury, local microenvironment changes 
due to hypoxia and the presence of dead or damaged cells lead to inflammation and immune 
response. MSCs respond to injuries, inflammation, and tumors in a way similar to that of the 
immune cells (Spaeth, Klopp, Dembinski, Andreeff, & Marini, 2008). MSCs can sense the 
pro-inflammatory cytokines released and migrate from the stem cell niche to the damaged 
site, where they cross-talk with the surrounding microenvironment. For example, MSCs are 
attracted by proteins such as stroma-derived factor 1 (SDF1) that binds to the receptor 
CXCR4 (Homing, Stem, Whiteman, & Ph, 2007). Once MSCs have engrafted at the damaged 
site, they release a spectrum of bioactive molecules that orchestrate tissue repair. MSCs first 
secrete soluble immunomodulatory and trophic factors that suppress both transient and 
continuous immune surveillance. For instance, MSCs inhibit the activity of natural killer 
cells, helper T cells, and cytotoxic T cells while activating the generation of regulatory T 
cells. After this potent immunosuppressive activity, MSCs participate actively in the support 
of homeostasis by active inhibition of apoptosis. The sum of these actions starts tissue 
remodeling and enhances the healing process (Maxson, Lopez, Yoo, Danilkovitch-Miagkova, 
& Leroux, 2012). Thus, it is currently believed that the therapeutic potential of these cells 
does not depend only on their stemness, but also on their secretory paracrine activities that 
include the secretion of extracellular vesicles (EVs) and exosomes. 
The self-healing capacity of the human body is limited and when the injury is extensive, 
or the number of MSCs that migrate to the damaged tissue is insufficient, the tissue cannot be 
repaired by local MSCs. The ability of MSCs to migrate to areas of injury in a range of 
pathologic conditions suggests that they may be ideal vectors for therapeutic delivery and 
MSCs have been proposed as promising therapeutic tools for regenerative medicine purposes. 
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A large number of investigators have demonstrated that MSCs are easily obtained from tissue 
biopsies, can be easily expanded in culture, are relatively non-immunogenic and have a 
remarkable plasticity, thus having the potential to differentiate into cells that have the 
characteristics of several mesenchymal lineages. MSCs also express low levels of major 
histocompatibility complex I and do not express major histocompatibility complex II, which 
renders the allogenic use possible (Le Blanc, Tammik, Rosendahl, Zetterberg, & Ringdén, 
2003). The sum of these features make MSCs the most commonly used adult stem cells in 
therapies for tissue engineering and regenerative medicine. 665 MSC-based clinical trials are 
listed in the database of the National Institute of Health (www.clincaltrials.gov) (October 31 
2016). Most of the trials registered at the site are Phase I/II clinical trials in which MSCs are 
used to treat a vast array of conditions (Squillaro, Peluso, & Galderisi, 2016).  
3. Mesenchymal stem cells and tumors 
Tumors are defined as a wound that never heals (Dvorak, 1986). Malignant 
transformation of cells is associated with a loss of the growth inhibition and invasion of the 
surrounding tissues. At first, tumor growth causes changes in the microenvironment that are 
similar to those caused by tissue injury or stress. Local cells react to the stress and provide 
support with the creation of the tumor stroma. Tumor stroma provides structural support as 
well as biochemical and mechanical cues to tumor cells. Tumor stroma also supports the 
uncontrolled tumor growth, which causes the destruction of tissue organization. This sets in 
motion a self-feeding spiral of events. When tumor growth reaches a certain level, the body 
reacts with inflammation and the immune reaction, together with the hypoxic environment 
and growth factors, chemokines, and cytokines released by tumor cells, actively promote 
MSCs migration from the niche to the tumor stroma which can support tumor progression 
(Sung et al., 2008)(Pietras & Östman, 2010)(Spaeth et al., 2008). Beside the migration of 
MSCs to the tumor site caused by inflammation, a range of tumors actively attract MSCs, 
such as colon and pancreatic cancer, breast and ovarian cancer, gliomas, osteosarcomas and 
melanomas. MSCs have tropism for gliomas. MSCs migrate and localize glioma cells via 
platelet-derived growth factor, epidermal growth factor, and stromal-derived factor-1-
mediated tropism(Pretheeban, Lemos, Paylor, Zhang, & Rossi, 2012). Furthermore, several 
researchers have proved that tumors provide a permissive environment for engraftment of 
exogenous implanted MSCs (Karnoub et al., 2007)(Nakamizo et al., 2005) (Studeny et al., 
2002)(Belmar-Lopez et al., 2013).  
This is relevant for the clinical application of ex-vivo expanded MSCs because when 
MSCs are administrated in patients, they could be engrafted in the tumor stroma and interact 
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with cancer cells. The concern is that once MSCs are in the tumor stroma by suppressing the 
immune system, they could promote tumor immune evasion and by inhibiting apoptosis, 
stimulating mitosis, and enhancing angiogenesis, they could cause an increase in tumor 
growth. In-vivo experiments were performed and resulted in the demonstration that 
administered MSCs engraft in cancer stroma and increase cell metastasis (Karnoub et al., 
2007)(Suzuki & Sun, 2011). In contrast, administered MSCs have been shown to have an 
anti-tumor activity in several types of tumors (Cortes-Dericks, Froment, Kocher, & Schmid, 
2016). In these publications, diverse mechanisms have been reported to be involved in the 
antitumor potential of MSCs. It has been observed that MSCs release soluble factors which 
contribute to the reduction of tumor growth and tumor progression (Khakoo et al., 2006).  
In conclusion, MSCs inherent specific tropism for tumors makes MSCs ideally suited 
system able to have a specific and local release of therapeutic agents to the tumor site. A 
number of animal studies have raised concerns that the implant of MSCs can increase tumor 
growth and metastasis (Karnoub et al., 2007; Spaeth et al., 2008), while the implant of MSCs 
has been shown to be beneficial in others (Khakoo et al., 2006). While this topic is still 
controversial and studies are performed to elucidate why the administration of MSCs has been 
shown to be detrimental in several in vivo animal models, the exploitation of MSCs as a 
cellular vehicle is essential for the improvement of anticancer therapies and should go on.  
4. Mesenchymal stem cells as a vector of antitumor therapy  
The first seminal publication that proved that MSCs can be used to deliver therapeutic 
agents to treat cancer was published in 2002 (Studeny et al., 2002). In the following years, 
more than 100 papers have been published in which MSCs have been used to deliver 
therapeutic agents directly to the tumor. In the majority of these papers, MSCs are genetically 
modified to express and release proteins. MSCs have been engineered to deliver proteins that 
cause a direct or indirect tumor death. MSCs have been also loaded with oncolytic viruses, 
chemotherapeutic agents and nanoparticles that have anti-tumorigenic properties. 
4.1 Genetically modified mesenchymal stem cells 
MSCs can be easily genetically engineered, using the available molecular techniques 
to express genes of interest. MSCs have been genetically modified for both regenerative 
medicine purposes and to treat a wide array of diseases (D’souza et al., 2015). For example, 
MSCs have been genetically modified to express BMP 2 to enhance bone density. Turgeman 
et al demonstrated this by engineering MSCs to express BMP2 in order to enhance bone 
formation in osteoporotic rats (Turgeman et al., 2001).  
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MSCs have been genetically modified to deliver therapeutic agents to tumor cells as 
well. For example, MSCs are being engineered to express genes that improve the immune 
response, genes that induce cell death of tumor cells, and genes that enable radio nucleotide 
uptake. Viral vectors, such as lentivirus, retrovirus, and adeno-associated virus, have been 
used for long term transgene expression in MSCs. Non-viral gene delivery methods have been 
used as well. In these studies, the therapeutic efficacy of genetically engineered MSCs has 
been shown in diverse experimental localized and metastatic tumor types. 
4.1.1 Mesenchymal stem cells engineered to express cytokines that enhance 
endogenous immune response to cancer cells. 
Cytokines have been widely used in the innate and adaptive immune responses against 
tumors. However, systemic treatment with recombinant proteins is frequently associated with 
severe side effects in immunotherapy. Therefore, a selective delivery system that accumulates 
the cytokines within the tumor microenvironment may be more effective and minimize side 
effects. 
4.1.1.1 Mesenchymal stem cells engineered to express interferons 
Interferons (IFNs) display a multitude of anti-tumor biological activities, including 
activation of the immune response, antiproliferative and proapotiotic apoptosis effects. 
However, in vivo systemic administration of high doses of IFNs have undesired side effects 
caused by the excessive toxicity. Furthermore, IFNs have a short half life and the protein may 
not reach the required concentration to be effective at tumor site. The first use of MSCs as a 
vector for antitumor therapy was published in 2002 by Studeny (Studeny et al., 2002). In this 
paper, the authors used an adenoviral vector to genetically engineer MSCs to express IFN- a 
strong antiproliferative cytokine that is known to have anticancer properties. Results showed 
that genetically engineered MSCs were able to engraft in tumor stroma and to increase the 
survival of mice implanted with the human metastatic melanoma cell line A375SM. The 
efficacy of the engineered MSCs was demonstrated both when MSCs were co-implanted with 
the melanoma cells and also when MSCs were injected systemically after establishment of 
pulmonary metastasis (Studeny et al., 2002). Although the effect was temporary and not 
sufficient to eradicate the tumor, these striking results demonstrated that this therapeutic 
approach was sufficient to obtain locally a concentration of IFN- that was able to decrease 
the growth of such an aggressive tumor, while the same effect was not obtained with systemic 
infusion of IFN-. Local secretion of IFN- is preferred because it reduces systemic toxicity. 
In a subsequent paper, these authors demonstrated that after establishing pulmonary 
metastasis with the melanoma cell line A375SM and the breast tumor cell line MDA 231, 
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three doses of intravenously injected MSCs genetically engineered to express IFN-double 
mice’s survival. The same result was not obtained when MSCs expressing IFN-were 
implanted subcutaneously. In MDA 231, pulmonary metastasis intravenously injected MSCs 
colonized the tumor and participated in the formation of the tumor stroma. Only a small 
number of MSCs were found in the liver after necroscopy (Studeny et al., 2004). Studeny’s 
proof of concept demonstrated that MSCs could be used as a vector to deliver selectively 
therapeutic agents to the tumor and paved the way for future work. 
Nakamizo et al. have investigated the tropism of labeled MSCs in vivo and demonstrated that 
MSCs injected in the carotid artery selectively migrate to Glioma. They showed in vitro that 
MSCs migrate toward Glioma. The authors performed intracranial injection of U87 and 7 
days later injection in the carotid 1 x10
6
 labelled MSCs. The authors demonstrated that MSCs 
are found only in the tumor and were absent from the normal brain parenchyma. Results were 
confirmed injecting the same number of MSCs in the opposite carotid. Comparable results 
were obtained also when LN229 and U251 tumor cells were implanted. The authors 
demonstrated that the tropism is maintained even when the MSCs are injected in the 
contralateral hemisphere of the brain, while control fibroblasts remained in the site of the 
injection. With this paper the authors provided a proof of principle in vivo that MSCs 
expressing IFN- are effective against intracranial gliomas. They provided evidence that 1 
x10
5
 MSCs expressing IFN- are necessary to increase mice survival when injected 
intratumorally, and they demonstrated that subcutaneous implant of 1 x10
5
 MSC expressing 
IFN- is not effective, implying that MSC intratumoral implants support tumor progression 
(Nakamizo et al., 2005). 
The homing of MSCs to tumor stroma was also shown in a murine immunocompetent 
model of prostate cancer pulmonary metastasis. The intravenous injection of 5 x10
5 
MSCs 
induced to express INF- by an adenoviral vector reduced tumor growth and doubled mice’s 
life span (C Ren et al., 2008). In a related study, Ren et al. have confirmed preferential 
homing of MSCs to lung tumor. The authors also showed, in a murine model of pulmonary 
metastasis of melanoma, that intravenous injection of 5 x10
5 
MSCs expressing murine INF- 
by an adeno-associated vector can increase life span compared to control animals (Changchun 
Ren et al., 2008). 
IFN- has been successfully used in the therapy of chronic myelogenous leukemia. Li 
et al. genetically modified MSCs to express IFN- to treat Chronic Myelogenous Leukemia. 
In this in vitro study, cocultures of MSCs decreased K562 proliferation in 5 days because 
K562 cells are blocked in G1 (X. Li et al., 2006). 
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MSCs genetically engineered to express INF-are currently tested in a phase one 
clinical trial (NCT02530047) in which the maximal tolerated dose is investigated in patients 
affected by ovarian cancer. In this clinical trial, patients will receive intra-peritoneal infusion 
starting from 1 x10
5
 MSC/Kg once a week for 4 weeks up to 4 dose levels.  
4.1.1.2 – Mesenchymal stem cells engineered to express interleukin 2 
The first report that MSCs can be used to deliver the antitumoral cytokine Interleukin 
2 (IL-2) was published by Stagg et al. who genetically modified MSCs to express IL-2. MSCs 
were co-injected with the poorly immunogenic melanoma cell line B16 in C57bl/6 normal 
mice. The authors used two different models. In the first model, co-injection of MSCs at 
several doses (5 x10
4
, 5 x10
5
, 5 x10
6
 ) and B16 cells resulted in a delayed tumor growth and 
prolonged mice survival compared to control mice. In the second model, when IL-2 gene 
modified MSCs embedded in matrigel were implanted in the vicinity of a pre-established 
tumor, 90% of the mice failed to develop tumors. These results demonstrated that IL-2 
delivery by MSCs adjacent to pre-established, low-burden tumor implants produces an 
immune response against the tumor that results in significantly delayed tumor growth (Stagg, 
Lejeune, Paquin, & Galipeau, 2004). 
Nakamura et al. engineered MSCs to express IL-2 using an adenoviral vector. The 
efficacy of these cells was tested in a rat model established with the glioma cell line 9L, in 
which the efficacy of IL-2 was already proved. The authors used two models. In the first, the 
MSCs were co-implanted, in the second, the MSCs were intra-tumorally injected after 3 days. 
Results demonstrated that MSCs implanted in the contralateral hemisphere have a tropism 
toward syngeneic glioma in rats. They further showed that survival of glioma-bearing rats 
increased in both models after MSCs injection. Prolonged survival caused by MSC-IL-2 was 
associated with inhibition of tumor growth as measured by MRI (Nakamura et al., 2004). 
4.1.1.3 Mesenchymal stem cells engineered to express interleukin 12 
Interleukin 12 (IL-12) is a pro-inflammatory cytokine that has several effects. 
Produced by antigen presenting cells, IL-12 induces the proliferation of Natural Killer and 
cytotoxic T lymphocytes. IL-12 induces also the production of IFN- that upregulates major 
histocompatibility complexes and adhesion molecules resulting in an enhanced antitumor 
immunity. Administration of IL-12 protein, or DNA, promotes cellular immunoregulatory 
responses against tumors affecting tumor growth. However, IL-12 is effective only at a high 
dose range that usually has toxic effects and this has hindered the clinical application of IL-12 
(Meko, Yim, Tsung, & Norton, 1995). Therefore, a system that would activate the 
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immunological reaction directly in the cancer stroma without causing systemic toxicity would 
be ideal. 
In 2006 Chen et al. published an interesting paper in which MSCs genetically 
engineered to express IL-12 of mouse origin were used as a preventive strategy. The authors 
inject the MSCs in the peritoneum of mice one week before the injection in the fat pad of 
ectopic lung, melanoma and hepatoma tumors. The treatment prevented the formation of a 
tumor in 95% of the cases. The authors suggested a prophylatic use of MSCs. These results 
suggest that the engineered MSCs are effective especially if the dimension of the tumor is 
small (X. C. Chen et al., 2006). In another study by the same group, the authors investigated 
the efficacy of MSCs engineered to express IL-12 in 3 RAT ectopic tumor models 
(melanoma, breast tumor, hepatoma) to test their anticancer and antimetastatic activity. They 
treated animals with injection of engineered 1 x10
6
 MSCs 4 times in a 20 days period. The 
results indicate that the treatment led to a significant reduction of the lung metastasis in the 
tumor models (X. Chen et al., 2008). Elazouk et al. retrovirally transduce MSC to express IL-
12 and they inject the MSCs in 2 mouse melanoma models. In one model, the tumor was 
established subcutaneously in the flank of the mice and the mouse melanoma cells B16F10 
were implanted. When the tumor reached 20mm
3
, 7,5 x10
5
 engineered MSCs were injected. 
The mice developed antibodies against the human cells and most of the human MSCs did not 
survive in the mice, after 7 days only 7% of the human MSCs remained. In spite of the 
reduced survival, injection of the engineered MSCs decreased the tumor’s volume and 
increased the life span of the mice. In the second model, they first injected the mice with 7.5 
x10
5
 engineered MSCs and later injected 7.5 x10
5 
B16F10 cells in the tail vein to establish 
lung metastasis. With this prophylactic treatment they were able to decrease the number of 
metastases by at least 50% (Elzaouk, Moelling, & Pavlovic, 2006). Seo et al. tested several 
injection routes of MSCs engineered to express IL-12. When control MSCs were injected, 
MSCs did not alter tumor progression, while intra-tumoral injected engineered MSCs 
outperformed intravenous injection and decreased tumor growth and metastasis formation, 
and increased animal life compared to controls. Best results were obtained with intratumoral 
injection of engineered MSCs embedded in matrigel (Seo et al., 2011). 
4.1.1.4 Mesenchymal stem cells engineered to express CXC3CL1 
Soluble CXC3CL1 (Fractalkine) is a member of the CX3CL family and exists in both 
membrane-bound and soluble forms. The soluble form induces the migration of cells 
expressing the receptor CX3CR1, such as monocytes, NK cells and T cells. Intratumoral 
injections of CXCL1 have a strong immunostimulatory effect that causes a strong antitumoral 
effect (Xin et al., 2005). Xin et al. demonstrated that intravenous injected MSCs engineered 
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using an adenovirus vector CX3CCL1 in mice bearing lung metastasis of adenocarcinoma and 
melanoma cells localize in the tumor stroma in the lungs. Engineered MSCs decrease lung 
meta growth and double mice’s survival (Xin et al., 2007). In another study, the authors 
demonstrated that 7 days after intratracheal injection, MSCs localize within and around lung 
metastasis more than in the healthy lungs. In both cases, in the adenocarcinoma and lung 
carcinoma metastasis models, intratracheal injection of MSCS engineered to express 
CXC3CL1 12 days after tumor establishment decreased the number of metastases and 
prolonged the survival of the mice. In the adenocarcinoma model, the mice survived 5 times 
more than the controls, while in the lung metastasis survived 3 days longer (Xin et al., 2009).  
4.1.2 Mesenchymal stem cells engineered to express antiangiogenic proteins 
4.1.2.1 Mesenchymal stem cells engineered to express NK4 
The blood supply is crucial for the tumor survival and for the dissemination of the 
metastasis. Several antinagiogenic approaches have been employed in oncology and some of 
them are successful. MSCs have been engineered to express antiangiogenic proteins such as 
NK4 that is an agonist of hepatocyte growth factor (HGF), a multifunctional growth factor 
that supports tumor growth, angiogenesis and lymphogenesis. NK4 antagonizes the 
phosphorylation of cMet by HGF. In vivo systemic administration of NK4 adenoviral vectors 
in mice that received subcutaneous tumors causes a strong antitumor effect, but also severe 
adverse effects (Maemondo et al., 2002). Kanehira et al. studied the efficacy of 1 x10
5 
MSCs 
engineered with an adenovirus vector to express NK4 in a mice model of pulmonary 
metastasis of colon carcinoma. They demonstrated a preferential homing of systemically 
injected engineered MSCs to tumor lung metastasis, compared to normal tissue. MSCs that 
expressed NK4 reduced the number of lung metastases, increased the survival of tumor 
bearing mice, and reduced angiogenesis and lymphogenesis (Kanehira et al., 2007). In another 
study, Haber et al. assessed the feasibility of therapeutic ultrasound to transfect MSCs with 
pDNA encoding for PEX, a protein that inhibits tumor angiogenesis in an ectopic prostatic 
cancer animal model. Results showed that 1 x10
6 
MSCs expressing PEX can induce a 70% 
decrease in tumor volume, with a single intravenous injection that can reach an 84% decrease 
when the injections are three (Haber, Baruch, & Machluf, 2017).  
4.1.3 Mesenchymal stem cells engineered to express proapoptotic proteins. 
4.1.3.1 Mesenchymal stem cells engineered to express TRAIL 
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a membrane 
ligand from the tumor necrosis factor (TNF) family. TRAIL is a ligand that induces apoptosis 
primarily in tumor cells by binding to certain death receptors TRAIL-RI and TRAIL-RII. 
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Most of normal cells, MSCs included, do not express the death receptors, and therefore are 
not affected by TRAIL expression. TRAIL has been used in different models of cancers in 
vivo, resulting in notable anti-tumor activity, making TRAIL an attractive therapeutic tool for 
tumor therapy (Siegmund, Lang, & Wajant, 2016). The efficacy of intravenous delivery of 
recombinant TRAIL is limited by the short half-life of the protein and frequent injections are 
needed in order to achieve the desired effect. Therefore, the use of MSCs engineered to 
produce TRAIL is a promising tool to be used in treatment of several types of cancer, because 
MSCs can be used as a constant source of this pro-apoptotic protein.  
Several authors were interested to test whether MSCs can function as a shield to 
protect the adenovirus from the immune system. Mohr et al. tested whether an intratumoral 
injection of MSCs expressing TRAIL was effective in an ectopic subcutaneous model of lung 
metastasis. TRAIL-expressing MSCs reduced tumor growth in the model causing diffused 
apoptosis (Mohr et al., 2008). Sasportas et al. investigated the effect of MSCs engineered with 
a lentiviral vector to express TRAIL in a preclinical model. Interestingly, MSCs survived 
longer when the tumor was implanted, compared to normal brain cells, suggesting that the 
two cell types cross talk, even if in vivo MSCs do not support tumor growth. They 
demonstrated that MSCs do not support the growth of the glioma in the brain but that MSCs 
migrate toward the glioma. Analysis of the efficacy demonstrated that co-implant of glioma 
and engineered MSCs in the brain of a mouse, as well as implant of the engineered MSCs 7, 
or 14 days after tumor implant resulted in reduction of glioma growth and increased survival 
of the tumor bearing mice (Sasportas, Kasmieh, Wakimoto, Hingtgen, & Water, 2009). In a 
similar paper, Leobinger et al. showed that lentiviral induced expression of TRAIL in MSCs 
was capable of reducing tumor volume in a lung metastatic tumor model obtained after the 
injection of the cell line MDAMB231 in the tail vein. MSCs were injected systemically 10 
days after the tumor cells engraft in the tumor stroma preferentially, compared to lung 
parenchyma. The injection of the engineered MSCs was effective and 3 of the 8 mice were 
tumor free (Loebinger, Eddaoudi, Davies, & Janes, 2009). Menon et al. injected the glioma 
cell line U87 and five days later ipsilaterally injected 6 x10
4 
MSCs lentivirally engineered to 
express TRAIL. Histology performed two weeks after MSCs injection revealed that the 
treatment reduced the tumor volume by 81.6% and the survival was increased form 37 days to 
almost 60 (Menon, Shi, & Carroll, 2009). In another study, the authors used MSCs obtained 
from the adipose tissue, the adipose stem cells (ASCs). The authors transfected ASCs in a 
stable manner to express TRAIL. In vitro, they demonstrated that coculture of ASCs 
expressing TRAIL induced apoptosis of Ewing sarcoma cell lines by cell-to-cell contact. In 
vivo ASCs engineered to express TRAIL inhibited tumor progression in two orthotopic Ewing 
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sarcoma models. Results indicated that when TRAIL is secreted by MSCs, it is more effective 
compared to the administrated TRAIL itself. They demonstrated also that cell to cell 
interaction was needed for ASCs expressing TRAIL to be effective. The authors investigated 
the importance of the timing of the injection of the ASCs in an animal model in which the 
Ewing sarcoma cells were injected in the muscle in the proximity of the tibia. Results 
demonstrated that when the ASCs were co-injected with the tumor cells, the treatment 
decreased the tumor volume by 75% at day 20 and more than doubled the life of tumor-
bearing mice. The treatment was not effective when the ASCs expressing TRAIL were 
injected after the tumor was already established (Guiho et al., 2016). 
4.1.3.2 Mesenchymal stem cells engineered to express TNF-
TNF- is a pleiotropic cytokine that induces tumor cell apoptosis. Tyciakova et al. 
tested the efficacy of the intravenous administration of 1 x10
6
 ASCs genetically modified to 
express TNF- in a model of melanoma lung metastasis. They could prove the homing of the 
engineered ASCs in the lungs (Tyciakova, Matuskova, Bohovic, & Kucerova, 2017).  
4.1.3.3 Mesenchymal stem cells engineered to express HSV-TK 
The herpes simplex type 1 thymidine kinase (HSVTK) has also been used as a 
“suicide gene” as a safety system in gene therapy experiments, allowing cells expressing the 
gene to be killed because HSVTK converts non-toxic gancyclovir into a toxic metabolite. In a 
rat experimental model of glioblastoma Miletic et al. demonstrated that MSCs induce 
HSVTK gene expression by a retrovirus migrate to the tumor and prolongation of the rats’ 
lifespan by 70% compared to control rats. Histology revealed that no tumor cells were 
detectable and a scar tissue was left in the mice. The scar tissue was filled with CD8, NK, and 
other immune cells (Miletic et al., 2007). Currently a phase I clinical trial designed to test the 
safety of MSCs genetically engineered to express HSVTK in patients with advanced or 
recurrent or metastatic gastrointestinal adenocarcinoma is currently undergoing in Germany 
(NCT02008539). 
4.1.4 Mesenchymal stem cells engineered to express proteins that enable the 
incorporation of radionucleotides 
Radioactive iodine is used to as a diagnostic and therapeutic tool in patients affected 
by thyroid carcinoma. Taking advantage of the fact that only thyroid follicular cells express 
the sodium-iodide symporter (NIS), a glycoprotein that transports both Na
+ 
and I
-
 ions, 
uptaken radioactive iodine by these cells enables to visualization (gamma emission) and 
killing (beta emission) of thyroid carcinoma cells. In a combined strategic approach, the 
capacity of NIS to concentrate radioactive iodine is exploited also for other types of tumors. 
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In this approach, MSCs are engineered to express NIS and once MSCs are engrafted in the 
tumor stroma they can uptake radioactive iodine causing local death in a range of few 
millimiters. For example, Dwyer demonstrated in vivo that intravenous (IV) and intratumoral 
injection of MSCs that express NIS engraft in the tumor and can reduce the tumor size after 
the injection of 
131
I (Dwyer et al., 2011). Results presented demonstrate that the IV injection 
is more effective compared to the intratumoral injection. The authors explain the difference in 
the effectiveness of the two types of injection based on the fact that intratumoral injection of 
MSCs does not reach all the tumor cells as reported also by Studeny (Studeny et al., 2002), 
and Nakamura (Nakamura et al., 2004). 
4.2 Mesenchymal stem cells as an anticancer cargo  
MSCs can deliver traditional anticancer drugs without requiring genetic manipulation. 
MSCs can function as cellular cargo to deliver various anticancer therapeutic agents, such as 
chemotherapeutic drugs, nanoparticles and oncolytic viruses. Compared to the systemic 
infusion of these drugs, this strategy enables a selective delivery to the tumor site of elevated 
doses of the therapeutic agent that affects tumor cells and the associated microvessels, while 
keeping systemic toxicity at minimum.  
4.2.1 Mesenchymal stem cells loaded with chemotherapeutic agents 
The outcome for patients affected by some kind of tumor has greatly improved in the 
last 30 years, while for other tumors has not. The improvement of the outcome for patients 
affected by tumors, for example with breast and prostate cancer, is partially due to the 
intensive screening that enables the diagnosis of the disease at an early stage, and partially to 
the improvement of the treatments. For other patients affected by other tumors, such as the 
osteosarcoma, mesothelioma and tumor of the pancreas, little progress has been made. This 
can in part be explained by the reasoning that for these tumors the diagnosis is made at a later 
stage, and in part because chemotherapy is infused systemically and is not selective for cancer 
cells and kills also normal cells that are in active cell division. Thus, if these drugs were 
delivered directly to the tumors by MSCs, the tumor could be treated with high doses of the 
drugs while keeping systemic toxicity at a minimum. MSCs have a relatively slow kinetic of 
replication that enables MSCs to uptake high doses of the drugs and reach the target site 
before the drugs causes cell immobilization or death. In a first seminal paper by Pessina et al., 
the authors demonstrated that MSCs exposed in vitro to Paclitaxel (PTX) can uptake the drug 
and release it in the culture media (Pessina PLOS 2011). PTX is used to treat several types of 
cancers because it has antiproliferative and antiangiogenic properties. A prolonged block of 
the progression of mitosis can either trigger the cell to enter in G1 phase without undergoing 
anaphase several times, resulting in aberrant multinucleated cells, or trigger apoptosis. PTX 
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treatment can have serious side effects, therefore a selective delivery of PTX only to cancer 
cells can be beneficial. MSCs resistance to PTX is probably dependent on the capacity of 
these cells to pump out the drug and on the ability of these cells to enter a block of cell 
division after tubulin polymerization that does not activate the cell’s death mechanisms. P-
glycoprotein is an ATP-dependent drug efflux pump that is responsible for the uptake and the 
efflux of drugs and controls the concentration of some drugs within the cell. MSCs are the 
ideal carrier of toxic drugs because MSCs overexpress P-glycoprotein. P-glycoprotein 
overexpression makes MSCs highly drug resistant. Therefore, MSCs can be exposed to 
concentrations of drugs that are lethal for cancer cells without consequences. MSCs can 
acquire anti-cancer activity upon exposure to high doses of chemotherapeutic agents, such as 
PTX, because MSCs can release the uptaken drugs in the tumor stroma. The authors 
demonstrated that exposure of MSCs to PTX resulted in a moderate accumulation in S and 
G2-M phase and in a modest induction of apoptosis without affecting their viability and 
functions. In vitro, the PTX released by MSC was sufficient to inhibit tumor and endothelial 
cell proliferation (Pessina et al., 2011)(Pascucci et al., 2014). Similar results were obtained 
when MSCs were exposed to other chemotherapeutic agents such as doxorubicin and 
Gemcitabine (L. Li et al., 2011)(Bonomi et al., 2015), while MSCs contrarily do not uptake 
pemetrex (Petrella et al., 2017). Other authors have demonstrated that PTX reduces, but not 
impairs MSCs’ ability to migrate (Duchi et al., 2013)(Pacioni et al., 2015). PTX released by 
MSCs is also released via exoxosmes. MSCs are known to secrete membrane microvecicles 
(MVs) (that range in size from 20 to 900 nm) and exoxosomes (that are more homogenous in 
size ranging from 20 to 200 nm) to communicate among cells. Pascucci et al. demonstrated in 
vitro that PTX uptake does not alter MSCs cytokine secretion. PTX is released by MSCs via 
MVs and these MVs retain their antitumor activity (Pascucci et al., 2014). Once released, 
PTX can penetrate tumor cells (Duchi et al., 2013), increase the number of multinucleated 
tumor cells (Pacioni et al., 2015), and reduce tumor cell growth (Pacioni et al., 2015; Pessina 
et al., 2011). In vivo coinjection of MSC loaded with PTX resulted in the marked decrease of 
tumor volume in mice in which three different tumor types were established: prostate cancer 
(DU145 cells), melanoma (B16 cells) and glioblastoma, supporting that MSCs can be used to 
deliver PTX to tumors (Pessina et al., 2011). Similar studies have demonstrated that MSCs 
loaded with PTX reduce the growth of several tumors, such as leukemia, the growth of several 
subcutaneous tumor xenograft models, and the growth of glioblastoma multiform in a 
intracranial xenograft model (Pessina et al., 2013)(Pessina et al., 2013)(Pacioni et al., 2015). 
When MSCs are injected intravenously, they can reduce the formation of lung metastasis 
established with the melanoma cell line B16. Three doses of MSCs were intravenous injected 
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5, 10 and 15 days after the metastasis was established. MSCs loaded with PTX were found in 
the metastatic mouse models and a reduction of 90% of the metastasis was reached in a 
syngenic mouse model (Pessina et al., 2015). Conforti et al demonstrated in vitro that MSCs 
maintain their immunoregulatory and anti-inflammatory properties after PTX uptake. Results 
showed that PTX uptake increases the MSCs ability to inhibit peripheral blood mononuclear 
cells (Conforti et al., 2014) . 
4.2.2 Mesenchymal stem cells loaded with nanoparticles 
Nanoparticles (NPs) treatment of tumors exploits the enhanced permeation of the 
vessels of the tumor. The blood supply of the malignant tumors is abnormal; blood and 
lymphatic vessels are characterized by vascular hyperpermeability which allow the 
accumulation of the nanodrugs within the tumor tissue microenvironment. As a consequence 
of this passive mechanism, only a minor fraction of the injected NPs can accumulate in tumor 
cells and affect their behavior. Using MSCs as vehicle for NPs to treat tumors is advantageous 
for several reasons. For example, MSCs can deliver NPs directly to the tumor stroma, 
improving the pharmacokinetics and the bio-distribution of the NPs. MSCs can actively 
engraft also in underperfused tumor stroma, a location that free NPs cannot reach. Compared 
with systemic perfusion of NPs using MSCs as a delivery system is also advantageous 
because the amount/dose of the NPs required for the clinical treatment is inferior and because 
MSCs prevent excessive NPs from being cleared by specialized organs. The first proof of 
principles that MSCs could deliver NPs to the tumor stroma was published by Lobinger in 
2009. In this case, the authors loaded MSCs with superparamagnetic iron oxide nanoparticles 
(SPIO) to track the cells. They utilized the fact that SPIO can be tracked with MRI. They used 
a 9.4 T MRI system to show that SPIO labeled MSCs home to an ectopic subcutaneous breast 
cancer tumor, as well as to pulmonary breast cancer metastasis. MSCs could be detected in 
tumor metastasis within 1 hour and histology confirmed that MSCs migrated within the tumor 
(Loebinger). Li et al. have developed silica NPs that contain doxorubicin. In order to promote 
NPs uptake by MSCs, the NPs that contained doxoubicine and were conjugate with antibodies 
against CD73 and CD90 are selectively expressed on the MSCs’ surface. MSCs were resistant 
to doxorubicine. NPs upload did not interfere with MSCs proliferation or tropism toward 
glioma U251 cells. The authors demonstrated that MSCs released the NPs over several days 
and that NPs with doxorubicine increased tumor cell apoptosis (L. Li et al., 2011). In a 
successive study, Sadhukha et al. engineered PLGA nanoparticles that contained PTX. The 
advantage of having PTX in the NPs was that MSCs overexpress P-glycoprotein and could 
retain the drug more once it is incorporated in the NPs. Furthermore, the MSCs enable a 
specific delivery to the tumor stroma of the drug. PTX was loaded at the concentration of 
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148+ 5 g/ml. The NPs released 50% of the PTX on the first day and then 5% each day. By 
the 9
th
 day 90% of the PTX was released as measured by PHLC. Maximal NP uptake in 
MSCs was reached within 6 hours with an average 4.7 pg PTX per cell. MSCs released 
approximately 2% of the internalized PTX every 24 hours for 25 days. NPs internalization did 
not alter MSCs proliferation, survival, motility and differentiation. In in vitro co-culture of 
MSCs that have internalized the NPs with PTX with A549 lung adenocarcinoma and MA148, 
ovarian cancer cell lines resulted in growth inhibition of the tumor cells. Comparison of the 
bio distribution of intravenous injected NPs alone or loaded on MSCs in a mouse model of 
lung adenocarcinoma resulted in a selective and prolonged accumulation in the lungs when 
NPs are loaded on MSCs (Sadhukha, O’Brien, & Prabha, 2014). In a similar study, Wu et al. 
tested the efficacy of MSCs loaded with NPs in a breast cancer mouse model. The NPs tested 
had a core made of gold nanorod and an outlier of mesoporous nanosilica that was loaded 
with PTX. They demonstrated that when injected intratumorally, MSCs ensure a better 
distribution of the NPs throughout the tumor, compared to the injection of NPs alone. They 
demonstrated the efficacy of a combined strategy, photothermal activation of gold nanorods 
and the release of the PTX reduced tumor volume drastically (Wu et al., 2016).  
4.2.3 Mesenchymal stem cells loaded with oncolytic viruses 
In addition to their ability to deliver chemotherapeutic agents and nanoparticles, MSCs 
have been used to deliver live oncolytic viruses. Oncolytic viruses are an emerging class of 
therapies in oncology. Oncolytic viruses are replication-competent cells that have been 
genetically modified to infect and selectively replicate in cancer cells. Upon infection the 
virus highjacks the proteins of the cancer cells in order to replicate inside the tumor cells. 
Once that number of virus particles has reached a critical point, the cancer cell is lysed and 
the new virus particles are ready to infect neighboring cancer cells. Sequential rounds of 
infection can potentially eradicate the cancer. The use of oncolytic viruses, especially 
adenoviruses, has been proven to be safe, even if their efficacy is impaired by the limited 
amount of the virus that reaches the tumor cells. In intratumoral injection of oncolytic viruses, 
the major hurdle is that the tumor has areas of necrosis and edema that are difficult to reach 
with direct injection. In intravascular injection of oncolytic viruses, the immune system can 
destroy most of the administrated oncolytic viruses and if the dose of oncolytic viruses is 
increased to overcome this limitation, the treatment can became toxic for the patients 
(Fukuhara, Ino, & Todo, 2016). To overcome the problems associated with the delivery of 
oncolytic viruses, MSCs can be used as a vehicle for oncolytic viruses. The advantage is that 
MSCs can migrate directly to the tumor cells and are not recognized by the immune system, 
so they can safely deliver oncolytic viruses to the tumor. Oncolytic viruses have been reported 
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to have a slow kinetic that is compatible with time required by MSCs to reach the tumor site 
before they are destroyed by viral replication. Sonabend et al. infected MSCs with a 
replication competent oncolytic adenovirus (CRAd) that selectively kills tumor cells, but has 
a limited diffusion in the tumor far from the injection site. In this paper, they demonstrate that 
CRAd delivered by MSCs can infect glioma cells when injected 7 days after tumor implant in 
immunodeficient mice in vivo. They demonstrated that the virus can infect MSCs, that the 
infection does not prevent MSC migration toward glioma cells, and that the virus replicates in 
tumor cells (Sonabend et al., 2008). In another study, Komarova et al. implanted an ovarian 
cancer intraperitoneally in nude mice. After 20 days of the tumor implant they injected twice 
1 x 10
6 
MSCs loaded with oncolytic virus. They demonstrated that MSCs were detectable 
within the tumor and that survival of the treated mice was double compared to control mice 
(Komarova, Kawakami, Stoff-Khalili, Curiel, & Pereboeva, 2006). Clinical trials using MSCs 
to deliver oncolytic viruses are currently under way. Melen et al. have treated 17 non 
responder patients affected by neuroblastoma and other tumors with a compassionate 
treatment of Oncolytic viruses ICOVIR-5, delivered by MSCs. The number of treatments 
varied from 4 to 70 and the number of injected cells ranged from 150 x 1 x 10
6
 to 264 x 1 x 
10
6
. No adverse reactions were reported and the treatment was effective in a patient that 
responded to the therapy (Melen et al., 2016). 
5 Photodynamic therapy 
Photodynamic therapy (PDT) is a successful, clinically approved, and minimally invasive 
treatment that uses light to activate photosensitizer molecules to produce cytotoxic reactive 
oxygen species (ROS) that kill neighbor cells (Giribabu, 2017). Each photosensitizer is 
activated by light of a specific wavelength. Using photosensitizers that are activated in the 
near infrared spectrum, we can cause cell death also in deep tissues (Lin et al., 2015). PDT is 
used for a wide range of clinical applications including the treatment of the tumors. The 
selectivity of PDT treatment of cancer depends on the fact that photosensitizers tend to build 
up in tumors cells, so photoactivation can damage specifically tumor cells and the 
surrounding vasculature. For OS the data on the efficacy are currently limited to experimental 
mice and dogs. Burch et al. treated 8 dogs affected by OS of the distal radius. The dogs were 
treated with systemic administration of 0.4mg/kg of verteporfirin. The authors  exposed the 
photosensitizer to 690-nm laser light for 5 minutes. The laser is on a fiber optic cable for a 
total light dose of 500J/cm. After 48 hours the limb was amputated. The necrotic area was 
measured before and after the treatment. The area of necrotic tissue was 4 times larger after 
the treatment. Necrosis was confirmed by histology. Untreated dogs had no necrosis. In 
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conclusion, the paper proved that PDT is feasible and effective for OS. The results are 
encouraging also if the efficacy of the treatment could be improved (Burch et al., 2009). The 
use of PDT is limited by the route of administration when the photosensitizer is injected in the 
blood stream and can penetrate the skin. If the patients are exposed to sun light or bright 
indoor light, they can develop severe burns. The distribution of the photosensitizer has been 
improved by the incorporation of the photosensitizer in nanoparticles (Calixto, Bernegossi, de 
Freitas, Fontana, & Chorilli, 2016). The distribution of the photosensitizer can be more 
selective if MSCs are loaded with photoactivable NPs that can be released in the tumor stroma 
and activated “on demand” only at the desired site to selectively kill target cells. 
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CHAPTER 1 
Aims and objectives 
The aim of this PhD thesis is to develop an innovative strategy to be used as 
neodajuvant therapy for osteosarcoma patients that do not respond to current standard therapy. 
In our strategy we will take advantage of the tumor tropic characteristic of MSCs to make 
them a cellular based delivery system for photoactivable nanoparticles (FNPs). The objective 
of the first chapter is to demonstrate in vitro that MSCs can incorporate the FNPs and after 
photoactivation can release free reactive oxygen species causing the death of the tumor cells. 
Classical bi-dimensional cultures were intentionally selected because they are the best tools to 
obtain evidence at a singular cell level. 
Methods  
Photoactivable Nanoparticles 
Fluorescent photoactivable nanoparticles (FNPs) were provided by Dr. Greta Varchi’s 
group at the National Research Council, Institute for the Organic Synthesis and 
Photoreactivity, Via Gobetti 101, 40129, Bologna, Italy. The tri-component FNPs were 
composed of core-shell PMMA nanoparticles post-loaded with the photosensitizer, meso-
tetrakis (4-sulfonatophenyl). The external shell is decorated with primary and quaternary 
ammonium salts, able to electrostatically bind anionic porphyrins.  
Isolation, culture and immunophenotypic characterization of human 
mesenchymal stem cells  
MSCs were obtained from bone marrow samples obtained from 3 patients undergoing 
surgery at Rizzoli Orthopaedic Institute after obtaining informed consent according to a 
protocol approved by the Ethics Committee. MSCs were isolated through gradient separation 
and plastic adherence. Briefly, cells were transferred to 150-cm
2
 culture flasks with α-MEM 
supplemented with 20% lot-selected FBS and GlutaMAX™ 1%, incubated in a humidified 
atmosphere at 37°C with 5% CO2 and medium changed every 3-4 days. When the cells 
reached approximately 70-80% confluence, they were detached by mild trypsinization for 5 
minutes at 37°C and counted. Then 1/3 of the cells was reseeded into a new 150-cm
2
 flask.  
Human osteosarcoma cell line 
Human osteosarcoma cells (U2OSTubRFP cells) were cultured according to the 
Sigma-Aldrich instructions. Briefly, the culture medium was McCoy’s 5A and was 
supplemented with 10% FBS and 1% GlutaMAX™. The cells were maintained at 37°C, 95% 
humidity, and 5% CO2 and split 1:5 every 3 days. 
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FNPs uptake and photoactivation  
To determine the cellular uptake of the nanoparticles, we analyzed the fluorescent 
signal from the FNPs using a BD FACSCanto II (BD Bioscience, Frankiln Lakes, NJ, USA). 
MSCs loaded with 45 g/ml FNPs at the indicated time points were washed three times with 
PBS 1X and harvested by trypsinization. After centrifugation, the loaded cells were washed 
twice with PBS 1X, counted with NucleoCounter
®
 (Chemotec, Lillerod, Denmark) and 1x10
6
 
MSCs suspended in fresh PBS 1X and directly analyzed. 
MSCs were plated at a density of 2.5x10
4
 cells per 35 mm Glass Bottom Dishes 
(MatTek Corporation) and loaded with FNPs. Photoactivation was performed using a NikonTi 
Eclipse microscope equipped with temperature and CO2 controllers (Okolab, Ottaviano, 
Napoli, Italy), a DS-QiMc-U2 12 bit camera, and an AR1 confocal laser by exposing cells to 
10% of the maximum power of 405 nm laser (0.02 J/sec).  
In vitro cytotoxicity of FNPs on MSCs was evaluated using a cell metabolic assay by 
the reagent water soluble tetrazolium salt-1 (WST-1) following the manufacturer’s 
instructions. Briefly, cells were seeded in 96-well plates at a density of 2000 cells/well in 100 
l a-MEM containing 20% FBS. After overnight attachment, cells were treated with FNPs for 
1 hour and then immersed in a 90 l culture medium supplemented with 10 l WST-1. After 
4 hours of WST-1-incubation at 37°C and 5% CO2, the optical density of each well was 
measured by a microplate reader (Synergy HT, BioTek Winooski, VT, USA) set at 450 nm 
with a correction wavelength set at 690 nm.  
In a methylene blue assay, MSCs were fixed by adding 10% formol saline to each well 
for 30 minutes. Cells were then stained with filtered 1% (w/v) methylene blue in 0.01 M 
borate buffer (pH 8.5). After 30 minutes, excess dye was removed and the remaining dye was 
rinsed three times in 0.01 M borate buffer (pH 8.5). The cells were examined microscopically 
at that point. The dye was then eluted by adding 1:1 (v/v) absolute ethanol and 0.1 M HCl to 
each well. The plates were gently shaken and the absorbance at 650 nm (A650) was measured 
using a microplate spectrophotometer (Synergy HT, BioTek Instruments Inc., Winooski, VT 
USA). The photometer was blanked on control wells containing elution solvent alone. Each 
treatment condition was in quintuplicate. A linear relationship between absorbance and cell 
number was verified. 
For co-culture, MSCs were plated at a density of 2.5x10
4
 cells in a 6 well plate and 
treated with FNPs. After 1 hour of incubation, in order to eliminate any residual NPs 
containing medium, cells were washed three times with PBS 1X and harvested by 
trypsinization. After centrifugation the labelled MSCs were washed twice with PBS 1X, 
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counted with NucleoCounter® and 2.5x10
4
 cells reseeded in 35 mm Glass Bottom Dishes 
(MatTek Corporation) in complete medium. In the same plates, U2OSTubRFP were seeded in 
a 1:5 ratio, let adhere overnight and then imaged as described above for photoactivation and 
time lapse imaging. 
The LIVE⁄DEAD® Viability⁄Cytotoxicity Kit quickly discriminates live from dead cells 
by simultaneously staining with green-fluorescent calcein-AM to indicate intracellular 
esterase activity and red-fluorescent ethidium homodimer-1 (EthD1) to indicate loss of 
plasma membrane integrity. For our analysis and after photoactivation, cells were incubated 
with the staining solutions according to the manufacturer’s protocol. The apoptotic index was 
calculated as the percentage of ethidium positive apoptotic nuclei divided by the total number 
of nuclei visualized by counterstaining with Hoechst and obtained from counts of randomly 
chosen microscopic fields in the irradiated areas.  
Results and Discussion 
FNPs uptake by MSCs  
 As a first step, we needed to demonstrate that FNPs could be uptaken and retained by 
MSCs for a time that was consistent with the migration of the MSCs from the injection site to 
the tumor stroma. The three major concerns were: 1) that MSCs would not uptake the FNPs, 
2) that the MSCs would not retain the FNPs and 3) that the FNPs would be expelled in a short 
time frame by the MSCs. Fluorescent FNPs uptake by MSCs cells was investigated by 
exposing MSCs to 45 mg/mL FNPs for 60 minutes. Flow cytometry with a FACS scan 
analyser was used to quantify the FNPs uptake and after 60 minutes, fluorescence signal was 
detected in 85% of the cells. Using the fluorescent microscope, it was clearly visible that the 
fluorescent signal of the FNPs was in the cellular cytoplasm (green in Fig. 1). FNPs tended to 
form aggregates and were still detectable after 72 hours. Taken together, these results 
confirmed that MSCs efficiently internalized the FNPs and were able to retain the FNPs for a 
time that was compatible with the migration of the implanted MSCs to the tumor site.  
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Figure 1. Intracellular distribution of FNPs in loaded MSCs. A confocal microscope image of cells loaded for 60 
minutes with 45 g/ml FNPs and observed after 72 hours with a Nikon confocal microscope with a SFluor 40X 
Oil DICN2 objective. Scale bar is 50 m. 
 As a second step, we needed to demonstrate that FNPs did not affect MSCs survival. 
MSCs were exposed to 45 mg/mL FNPs for 60 minutes in the dark to avoid the activation of 
the photosensitizer. To evaluate the cytotoxicity, methylene blue and WST-1 assay were 
conducted. Both assays’ results showed no significant decrease in cell proliferation up to 7 
days from the initial loading of the FNPs.  
 As a third step we needed to demonstrate that FNPs did not affect MSC motility. Live 
cell time lapse observations clearly showed that motility of loaded MSCs is not altered by the 
presence of intracellular FNPs when compared to unloaded cells (data not shown). We can 
conclude that exposure of MSCs to 45 mg/mL FNPs for 60 minutes in the dark does not affect 
MSC viability, nor does it affect the motility.  
FNPs loaded MSCs induce OS cell death after Photactivation 
 In order to test whether photoactivation of the MSCs loaded with the FNPs could induce 
OS cell death, we conducted a co-culture of the MSCs with the OS cell line U2OS. To be able 
to distinguish between the MSCs and the OS cells, we used the cell line U2OSTubRFP that is 
genetically engineered to express the protein tubulin in red. MSCs loaded with the FNPs 
without the photosensitizer were used as control. Photactivation was performed using the 
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laser of the confocal microscope. MSCs were subjected to illumination with a 405 nm laser 
(10% of the maximum power, 0.02 J/sec) for 10 seconds causing specific activation of the 
photosensitizer. The field of irradiation of the laser is indicated in the red square in Figure 2A. 
Laser light activation of a few FNPs within a single MSC resulted in rapid formation of 
bubble-like structures from the simulated cells in a short time frame that were indicative of 
cell damage and necrosis (Figure 2B). Also in a short time frame, the surrounding tumor cells 
that acquired a round shape detached from the plastic plate and died. Interestingly, subsequent 
activation of the FNPs within a single dead MSC was still able to induce cell death of the 
surrounding OS cells. Laser light stimulation of the control MSCs did not cause any cell 
damage. 
 
Figure 2. Co-culture assay of FNPs loaded MSCs with U2OSTubRFP cells seeded in a 1:5 ratio before A) and 
after B) photoactivation. The area of photostimulation is indicated in red square. Scale bar is 50 m. 
In order to quantify the effect of the photoactivation, a Live and Dead Assay was 
performed in the coculture of MSCs and U2OSTubRFP seeded in 1:5 ratio. Photoactivation 
was performed using 405 laser power at 0.16 J/sec for 1.5 minutes. After 24 hours the 
apoptotic index was calculated as the percentage of ethidium positive apoptotic nuclei divided 
by the total number of nuclei visualized by counterstaining with Hoechst obtained from 
counts of randomly chosen microscopic fields in the corresponding irradiated areas. The 
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percentage of apoptotic cells was 84% when the MSCs were loaded with the FNPs with the 
photosensitizer, while the percentage was around 4% when the MSCs were loaded with 
control FNPs.  
Overall, our results confirm in vitro that MSCs can be loaded with photactivable 
nanoparticles and that photactivation is able to eliminate both vehicle cells (MSCs) and tumor 
cells at the same time. The fact that the MSCs are eliminated as well is very important 
because as we have mentioned in the introduction, there is a concern that the MSCs can 
promote tumor growth. Moreover, the efficacy of the second photostimulation on the same 
FNPs demonstrated the opportunity to induce several and repeated cycles of photostimulation 
that could eventually be repeated if the first was not effective in the tumor eradication.  
Conclusions 
The first chapter demonstrated that FNPs are efficiently uptaken by MSCs at a 
concentration of 45µg/ml without evident sign of toxicity or inhibition of MSCs motility. 
Most importantly, these results indicate that our bio-system could represent an efficient and 
targeted delivery strategy in killing human OS cells, suggesting a novel therapeutic avenue for 
the treatment of bone sarcomas.  
The major limitation of the current FNPs is that the photosensitizer used in this first 
proof of concept can be activated in the visible spectrum and it is known that visible light 
does not penetrate into deep tissues.  
CHAPTER 2 
Aims and objectives 
The objective of the second chapter is to demonstrate in vitro and in vivo that FNPs with 
a photosensitizer that can be photoactivated in near infrared spectrum can trigger tumor cell 
death in tridimensional tissues.  
Methods 
Photoactivalble Nanoparticles 
The Fluorescent photoactivable nanoparticles (FNPs) were provided by Dr. Greta 
Varchi’s group at the National Research Council, Institute for the Organic Synthesis and 
Photoreactivity, Via Gobetti 101, 40129, Bologna, Italy. The particles are composed of a 
hydrophobic inner core of poly-PMMA covalently functionalized with allyl-fluorescein and 
surrounded by a hydrophilic shell of quaternary ammonium salts, suitable for the electrostatic 
loading of the tetra-anionic photosensitizer Tetrasulfonate aluminum phthalocyanine. FNPs 
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are characterized by an average hydrodynamic diameter of 80 nm. Activation of the 
photosensitizer by NIR-light generates cytotoxic reactive oxygen species (ROS), such as 
singlet oxygen (
1
O2), from oxygen molecules available in the surrounding environment. 
Cell cultures 
The androgen-independent human prostate carcinoma PC3 cell line was purchased 
from ATCC (CRL-1435) and cultured in a 1:1 ratio with HAM’S and F12:DMEM-hg, 10% 
FBS, with 1% GlutaMAX™ and 50 U ml-1 penicillin/streptomycin. RLuc-PC3 cell line, 
permanently transfected with RLuc-pRC-CMV vector, were provided by professor Jeronimo 
Blanco’s group of the Cell Therapy Group, Institute for Advanced Chemistry of Catalonia, 
CSIC; Networking Biomedical Research Center on Bioengineering, Biomaterials and 
Nanomedicine (CIBER-BBN), Barcelona, Spain. 
MSCs were obtained from bone marrow samples obtained from 3 patients undergoing 
surgery at Rizzoli Orthopaedic Institute after obtaining informed consent according to a 
protocol approved by the Ethics Committee. MSCs were isolated through gradient separation 
and plastic adherence. Briefly, cells were transferred to 150-cm
2
 culture flasks with α-MEM 
supplemented with 20% lot-selected FBS and GlutaMAX™ 1%, incubated in a humidified 
atmosphere at 37°C with 5% CO2 and medium changed every 3-4 days. When the cells 
reached approximately 70-80% confluence, they were detached by mild trypsinization for 5 
minutes at 37°C and counted. Then 1/3 of the cells was reseeded into new 150-cm
2
 flasks.  
Microtissues and PDT 
PC3 tumor tri-dimensional microtissues were prepared by co-culturing PC3 cells with 
MSCs at a 1:1 ratio and following an adaptation of the pellet culture method (Johnstone, 
Hering, Caplan, Goldberg, & Yoo, 1998). MSCs and PC3 cells, 1.25×10
5
 cells of each cell 
type, were mixed in a 1.5 mL polypropylene screw cap conical tube (Primo Euroclone, Milan, 
Italy), suspended in 0.5 mL DMEM-HG supplemented with 10% FBS, spun at 500 g for 5 
minutes and the tubes, with caps partially loosened, directly incubated in humidified 
atmosphere at 37 °C with 5% CO2. After 72 hours, the cell pellets turn into compact spherical 
aggregates that easily detach from the tube and can be handled without loss of integrity. 
Following 3 days in culture, the microtissues were incubated for 10 minutes on a rotating 
plate with 18g/mL- FNPs washed with PBS and irradiated. PDT was performed using a 
668±3 nm LED (XLed McManton, Italy). Cell viability was assessed with a LIVE⁄DEAD® 
Kit.  
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In vivo study 
Adult 6-week-old SCID mice (n = 30) were purchased from Charles Rivers 
(Wilmington, MA, USA) and kept under pathogen-free conditions in laminar flow boxes. 
Animal maintenance and experiments were performed in accordance with national and 
international established guidelines and after the approval of the Ethical Committee. For 
tumor cell inoculation, animals were anesthetized by intra-peritoneal injections of 3.3 mg/kg 
of xylazine (Henry Schein, Melville, NY,USA) and 100 mg/kg of ketamine (Merial, Duluth, 
GA, USA). Luc-PC3 (5 x 10
5
 cells) suspended in 50 mL DMEM were injected 
intramuscularly in each thigh muscle. After 2 weeks, mice were randomly assigned to the 
different treatment groups, n = 10 for each treatment modality. Twice a week, mice were 
treated by intratumoral inoculation of 25µg-FNPs and 25µg/mL FNPs without the 
photosensitizer in 50 µl volume, or PBS 50 µl as a control for 4 weeks. Mice were irradiated 
with an array of multiple max = 668±3 nm LEDs at 4 cm from the tumor surface for a 
duration of 5 minutes (fluence 8.04 J/cm
2 
- 26.8 mW/cm
2
). In vivo bioluminescence (BLI) of 
engrafted tumors was performed as follows. Mice were anesthetized intra-peritoneally and 
then injected with 150 L of luciferin (Caliper, 16.7 mg/mL in saline). Animals were placed 
in the detection chamber of the high efficiency Imag-EM-X” EC-CCD imaging system from 
Hamamatsu Photonics and images were acquired from the dorsal direction during a 1 minute 
period. A second image of the animal was obtained using a white-light source inside the 
detection chamber to register the position of the luminescence signal relative to the mouse. 
Mice were imaged weekly. Quantification and analysis of photons recorded in images was 
done using the Wasabi image analysis software (Hamamatsu Photonics). Light measurements 
were expressed as LUX following subtraction of background. 
Analyses on tumor explants 
Tumors were explanted at the end of the therapy protocol (week 5). Explanted tumors 
were then prepared for cryosectioning and fixed in 1% Paraformaldehyde for 4 hours at room 
temperature, embedded in O.C.T. TM Compound (Tissue-Tek, Sakura, Leiden, Netherlands) 
and frozen in dry ice. Cryosections of 10m thickness were mounted onto glass slides and 
stained with H&E according to standard procedures. Images were acquired using an Axiophot 
ZEISS (Oberkochen, Germany). 
Results and discussion 
Photoactivation of FNPs in tumor microtissues 
The objective of this experiment was to prove that the FNPs with the photosensitizer 
could be activated in a tridimensional tissue and that the photoactivation could kill the tumor 
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cells. The three major concerns were: 1) the amount of photosensitizer on the FNPs would not 
be sufficient to trigger cell death, 2) that the irradiation would not reach the FNPs in a 
tridimensional tissue, and 3) that the photoactivation was not sufficient to reduce tumor 
volume. For this purpose, tumor microtissues were established as a simple tridimensional 
model of a tumor and the associated stroma. The microtissues were spheroids of 
approximately 1mm in diameter. The microtissues were incubated with 18g/mL- FNPs. 
Microtissues not exposed to the FNPs were used as control. In order to assess the effect of the 
photoirradiation on cell viability after irradiation, the microtissues were stained with calcein 
and ethidium that respectively stains live cells in green and dead cells in red. Confocal 
microscope images show (Figure 3A) that irradiated FNPs exposing irradiated microtissues 
were composed mostly of dead cells and lost their spherical structure, while irradiated control 
microtissues maintained their typical spherical shape and were composed mostly of viable 
positive cells (Figure 3A).  
 
Figure 3. Analysis of cell death on irradiated tumor microtissues. Representative 3D rendering of superimposed 
green (Calcein-AM, live cells) and red (EthD-1, dead cells) channels of confocal single 2D z-stacks from control 
and FNP-loaded irradiated PC3 microtissues.  
 
These results were consistent with the FNPs being photoactivable in a tridimensional tissue 
and being able to kill tumor cells.  
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In vivo Photodynamic therapy of solid tumors 
In order to demonstrate that the FNPs could be activated in vivo, SCID mice were 
intramuscularly implanted with Luciferase expressing PC3 (Luc-PC3) in both thighs. Tumors 
were allowed to develop during a two-week period until a noticeable luciferase signal was 
detectable. During a 4-week interval, the mice were divided in three groups that were then 
either injected or not with 25 µg FNPs, or with the same amount of photosensitizer (Plt) or 
PBS 50 µl (CTRL) and irradiated with an array of multiple max = 668±3 nm LEDs. Tumor 
growth was not affected in the control group in which the tumor grew exponentially. The 
irradiation of tumors treated with Ptl resulted in a significant reduction of tumor growth 
relative to controls as well as the irradiation of tumors treated with FNPs, which resulted in an 
even larger growth reduction effect (Figure 4).  
 
Figure 4. Photodynamic therapy of PC3 solid tumors in vivo. The graph represents the light events recorded in 
the acquired images (mean + standard error (bar) in the Y axis vs. time (X axis)). 
Tumors explanted at the end of the therapeutic protocol were cryopreserved and 
processed for histology and gene expression analysis. The histopathology of H&E-stained 
sections of tumors treated with FNPs or Ptl and irradiated showed multiple foci of necrosis, 
with condensed nuclei and loss of cells’ integrity. Irradiation of tumors treated with FNPs 
lead to the formation of widespread degraded areas composed predominantly of 
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necrotic/apoptotic cells as evidenced by the diffuse nuclear pyknosis, condensed nuclei, and 
cell debris. Monocytes and red cells from vessels damaged by PDT were also detected (Figure 
5A). Images from irradiated control mice (CTRL) revealed large tumor masses containing 
predominantly healthy tumor cells intercalated with the host muscular tissue. Multiple areas 
comprising aggregated cells undergoing mitotic division and euchromatic nuclei are clearly 
detected (figure 5B).  
 
Figure 5. Immunohistochemistry. Representative images of H&E stained 10 m tumor cryosections (100x). A) 
Necrotic tissue of mice injected with FNPs after photostimualtion. B) Vital tumor tissue in control mice.  
 
Overall these results demonstrated that once FNPs are photoactivated, they are able to reduce 
tumor growth.  
Conclusions 
The second chapter demonstrated that FNPs can be activated in the near infrared region 
of the visible spectrum, which can penetrate into deep tissues, and that FNP photoactivation 
results in tumor growth reduction in an animal model.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
The two chapters described in this thesis are two initial steps in a long journey that will 
eventually lead to the clinical application of MSCs loaded with photoactivable NPs in a 
clinical trial. As a next step, we must demonstrate that MSCs can effectively deliver the FNPs 
employed in chapter two in an animal model of OS. If we succeed in the reduction of tumor 
growth, the data collected will be useful for the request of authorization for the clinical trial.  
 
Figure 6. Representation of the supposed clinical application of the MSCs loaded with photoactivable FNPs. 
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